7.67
price down icon0.26%   -0.02
pre-market  시장 영업 전:  7.55   -0.12   -1.56%
loading
전일 마감가:
$7.69
열려 있는:
$7.66
하루 거래량:
3.96M
Relative Volume:
1.02
시가총액:
$794.46M
수익:
$45.97M
순이익/손실:
$-508.80M
주가수익비율:
-1.3996
EPS:
-5.48
순현금흐름:
$-382.65M
1주 성능:
-20.60%
1개월 성능:
-13.24%
6개월 성능:
-47.07%
1년 성능:
-67.01%
1일 변동 폭
Value
$7.52
$7.84
1주일 범위
Value
$6.83
$7.84
52주 변동 폭
Value
$5.90
$28.18

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
명칭
Intellia Therapeutics Inc
Name
전화
857-285-6200
Name
주소
40 ERIE STREET, CAMBRIDGE, MA
Name
직원
598
Name
트위터
@intelliatweets
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
NTLA's Discussions on Twitter

NTLA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NTLA
Intellia Therapeutics Inc
7.67 1.00B 45.97M -508.80M -382.65M -5.48
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-21 업그레이드 Wolfe Research Peer Perform → Outperform
2025-03-05 개시 H.C. Wainwright Buy
2025-02-28 다운그레이드 Goldman Neutral → Sell
2025-02-28 다운그레이드 JP Morgan Overweight → Neutral
2025-01-27 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-02-23 다운그레이드 Goldman Buy → Neutral
2024-02-15 개시 Wolfe Research Peer Perform
2023-04-13 개시 Canaccord Genuity Buy
2023-03-21 개시 Bernstein Outperform
2023-03-14 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-02-01 개시 Cantor Fitzgerald Overweight
2023-01-24 업그레이드 Citigroup Sell → Neutral
2023-01-19 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 개시 Morgan Stanley Overweight
2022-09-21 개시 JP Morgan Overweight
2022-09-01 개시 Citigroup Sell
2022-06-17 개시 BMO Capital Markets Market Perform
2022-06-16 개시 BofA Securities Buy
2022-04-28 개시 Credit Suisse Outperform
2022-02-18 개시 William Blair Outperform
2022-02-07 업그레이드 Oppenheimer Perform → Outperform
2022-01-31 개시 Cowen Outperform
2022-01-07 개시 Piper Sandler Overweight
2021-10-05 개시 Guggenheim Buy
2021-09-24 개시 Stifel Buy
2021-06-28 재확인 H.C. Wainwright Buy
2021-06-11 개시 H.C. Wainwright Buy
2021-05-07 업그레이드 ROTH Capital Neutral → Buy
2021-05-04 개시 RBC Capital Mkts Outperform
2021-03-04 개시 JMP Securities Mkt Outperform
2020-12-22 다운그레이드 Robert W. Baird Outperform → Neutral
2020-10-27 개시 Truist Buy
2020-10-14 개시 Wells Fargo Overweight
2020-09-18 개시 Goldman Buy
2020-02-28 업그레이드 Oppenheimer Perform → Outperform
2020-02-14 다운그레이드 Wedbush Outperform → Neutral
2019-11-01 업그레이드 Raymond James Mkt Perform → Outperform
2019-07-09 개시 Robert W. Baird Outperform
2019-06-10 개시 ROTH Capital Neutral
2019-05-03 업그레이드 Wedbush Neutral → Outperform
2019-04-12 개시 Evercore ISI Outperform
2018-11-02 다운그레이드 Wedbush Outperform → Neutral
2018-10-29 개시 Credit Suisse Neutral
2018-09-21 개시 Raymond James Mkt Perform
2018-05-15 업그레이드 Chardan Capital Markets Neutral → Buy
2018-03-08 개시 JMP Securities Mkt Outperform
2017-11-01 재확인 Jefferies Buy
2017-06-22 재개 Jefferies Buy
2017-03-28 개시 Chardan Capital Markets Buy
2016-08-05 업그레이드 Jefferies Hold → Buy
모두보기

Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스

pulisher
Jun 04, 2025

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView

Jun 04, 2025
pulisher
Jun 03, 2025

(NTLA) Investment Report - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus

Jun 03, 2025
pulisher
May 31, 2025

ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus

May 31, 2025
pulisher
May 30, 2025

Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga

May 30, 2025
pulisher
May 30, 2025

ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN

May 30, 2025
pulisher
May 30, 2025

StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News

May 30, 2025
pulisher
May 30, 2025

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN

May 30, 2025
pulisher
May 30, 2025

Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter

May 30, 2025
pulisher
May 30, 2025

Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus

May 30, 2025
pulisher
May 29, 2025

Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar

May 29, 2025
pulisher
May 29, 2025

ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia adverse event could resurface questions, says JPMorgan - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics Shares Drop 25 Percent After Liver Stress Reported in Gene-Editing Trial - geneonline.com

May 29, 2025
pulisher
May 29, 2025

Intellia tumbles on liver safety signal for CRISPR therapy - FirstWord Pharma

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia filing spurs safety concerns over CRISPR drug - BioPharma Dive

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga

May 29, 2025
pulisher
May 29, 2025

Intellia commercial position in question after safety event. says Goldman - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg

May 29, 2025
pulisher
May 29, 2025

Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue - BioSpace

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Study Concerns | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia stock holds $45 target despite AE concerns By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith - Fierce Biotech

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Stock Drops After Trial Update | NT - GuruFocus

May 29, 2025
pulisher
May 29, 2025

H.C. Wainwright maintains $30 target on Intellia stock post-safety update - Investing.com

May 29, 2025
pulisher
May 29, 2025

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews - Benzinga

May 29, 2025
pulisher
May 29, 2025

Cantor maintains Intellia stock at $65 target despite trial concern By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Intellia stock tumbles on safety concerns By Investing.com - Investing.com Canada

May 29, 2025
pulisher
May 29, 2025

Intellia stock tumbles on safety concerns - Investing.com

May 29, 2025
pulisher
May 29, 2025

Intellia stock down on safety concern for gene editing drug - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

NTLA: Intellia Therapeutics Advances Key Clinical Trials | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

BofA cuts Intellia stock target to $39, maintains Buy rating By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Intellia stock holds after JMP reiterates market perform - Investing.com Australia

May 29, 2025
pulisher
May 29, 2025

Intellia stock holds after JMP reiterates market perform By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study - TipRanks

May 29, 2025
pulisher
May 28, 2025

Intellia reports progress in Phase 3 clinical trials - Investing.com

May 28, 2025

Intellia Therapeutics Inc (NTLA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
자본화:     |  볼륨(24시간):